Amgen Announces BLINCYTO ® (blinatumomab) Five-Year Overall Survival Data At EHA 2019

Phase 2 Single-Arm BLAST Study Shows Median Overall Survival of 36.5 Months in Patients With Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia More Than Half of Patients who Achieved an MRD-Negative Complete Response Still Alive at Five Years Only CD19-Targeted Immuno-oncology Therapy With Five-Year Survival Data THOUSAND OAKS, Calif., June 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO® (blinatumomab) in patients with minimal residual disease (MRD)-positive acute lymphoblastic leukemia (ALL). The study found that with a median follow-up of 59.8 mo...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news